Form 4: Twist Bioscience Officer Sells Shares for Tax Obligation

Twist Bioscience's Chief Accounting Officer, Robert F. Werner, sold 186 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Robert F. Werner, Chief Accounting Officer of Twist Bioscience Corp. (TWST), sold 186 shares of common stock.
• The transaction occurred on August 4, 2025, at a price of $28.364 per share.
• This sale was a 'sell to cover' transaction, mandated by the issuer's equity incentive plans to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs).
• The sale was not a discretionary trade by Mr. Werner.
• Following this transaction, Mr. Werner beneficially owns 49,780 shares of Twist Bioscience common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine 'sell to cover' for tax obligations, not a discretionary sale, thus it has a neutral impact on sentiment as it does not reflect a change in the officer's view of the company's prospects.

Future Outlook

This filing, a Form 4, does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a 'sell to cover' transaction and do not represent discretionary trades by the Reporting Person.

Industry Context

Form 4 filings are routine disclosures for publicly traded companies, reporting changes in beneficial ownership by insiders. 'Sell to cover' transactions, where shares are sold to satisfy tax obligations arising from equity compensation like Restricted Stock Units (RSUs), are a common and standard practice across industries for executives and employees receiving stock-based awards.

Comparison to Industry Standards

• This 'sell to cover' transaction is a standard administrative procedure for executives receiving equity compensation, aligning with common practices observed across various industries and companies globally.
• The reported sale price of $28.364 per share reflects the market price at the time of the transaction, consistent with how such non-discretionary sales are executed.

Stakeholder Impact

• Shareholders: Minimal impact, as the transaction is a routine, non-discretionary sale for tax purposes and does not signal a change in management's confidence or company fundamentals.

Key Dates

Recommendation

This Form 4 reports a routine 'sell to cover' transaction by an officer to satisfy tax obligations related to RSU vesting. It is not a discretionary sale and therefore does not reflect a change in the officer's confidence in the company or its future prospects. As such, it provides no new information that would alter an existing investment thesis, warranting a 'hold' recommendation.

Keywords

Twist Bioscience, TWST, Form 4, insider transaction, beneficial ownership, stock sale, RSU, tax withholding, equity compensation